Related Experiment Video
Updated: May 10, 2026
05:12
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
Rivastigmine for vascular cognitive impairment
Jacqueline Birks1, Bernadette McGuinness, David Craig
1Centre for Statistics in Medicine, University of Oxford, Oxford, UK. jacqueline.birks@csm.ox.ac.uk.
The Cochrane Database of Systematic Reviews
|June 4, 2013
Summary
Rivastigmine shows some cognitive benefits for vascular cognitive impairment (VCI), but leads to significant side effects and withdrawals. Further research is needed to confirm its efficacy and safety in treating VCI.
Area of Science:
- Neurology
- Pharmacology
Background:
- Vascular dementia is the second leading cause of dementia, often co-occurring with Alzheimer's disease as mixed dementia.
- Vascular cognitive impairment (VCI) encompasses cognitive deficits without memory loss, lacking standard treatments.
- Cholinesterase inhibitors like rivastigmine, used for Alzheimer's, are being investigated for VCI due to shared neurotransmitter deficits.
Purpose of the Study:
- To evaluate the effectiveness of rivastigmine compared to placebo in treating vascular cognitive impairment (VCI), vascular dementia, and mixed dementia.
Main Methods:
- A systematic search of the ALOIS database (Cochrane Dementia and Cognitive Improvement Group) was conducted.
- Included were unconfounded, randomized, double-blind trials comparing rivastigmine with placebo.
- Data extraction and analysis were performed independently by two reviewers, including adverse effects.
Main Results:
- Three trials with 800 participants were included, with varying dementia severities and rivastigmine dosages.
- One trial showed no significant differences in cognitive, neuropsychiatric, or functional outcomes.
- A large trial indicated a statistically significant cognitive advantage for rivastigmine but reported significantly higher rates of adverse events and withdrawals.
Conclusions:
- Limited evidence suggests potential cognitive benefits of rivastigmine in VCI, primarily from one large study.
- Rivastigmine treatment is associated with a significant proportion of patients experiencing side effects leading to withdrawal.
- The efficacy and safety profile warrant careful consideration for rivastigmine use in VCI.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...